



**WORLD
TOUR
2026**



SAFETY FIRST



SAFETY FIRST



SAFETY FIRST

FUTURE OF PHARMACOVIGILANCE

UPCOMING EVENTS 2026



2nd European Drug Safety & AI Summit

Date: **February 24-25**
Location: **Barcelona**



3rd American MedTech Summit

Date: **April 8-9**
Location: **Chicago**



11th Pharmacovigilance & RWE 2025

Date: **May 13-14**
Location: **London**



3rd World Drug Safety Summit

Date: **June 9-10**
Location: **Basel**



3rd Global Drug Safety & PV Outsourcing Summit

Date: **September 22-23**
Location: **Mumbai**



4th American Drug Safety & REMS Summit

Date: **October 13-14**
Location: **Boston**



5th American Drug Safety & AI Summit

Date: **December 2-3**
Location: **San Diego**

KEY TOPICS

- Exploring Risk Management, Minimisation Measures And Effectiveness
- The Impact Of Recent EMA, FDA And CIOMS Guidance On Lifecycle PV Planning
- Navigating The Future Of Pharmacovigilance
- Future-Proofing Clinical Trials: Strategic Approaches To GCP Inspection Readiness And Management
- Artificial Intelligence And Machine Learning In PV: Practical Considerations
- Opportunities And Challenges Of A Global Pharmacovigilance System
- How RWE Is Transforming PV
- Integrated Evidence Planning In PV
- Use Of AI In Automation Of Signal Detection Tool
- Leveraging Generative AI In Quality Management: Enhancing Efficiency

TRUSTED GLOBAL PARTNER IN STRATEGIC EVENTS



The **Pharmacovigilance Tour 2025** is the innovative vision of the Why Summits team, a group with a combined century of expertise in orchestrating **2,800+ conferences** across all continents. With decades of proven success in industries including **Pharma, Biotech, and Medical Devices**, we've also pioneered strategies in areas like:

- Pharmacovigilance and Drug Safety
- End-to-end PV services
- Cross-functional collaboration
- Risk Management innovations
- And more



EXCLUSIVE AND STRATEGIC NETWORKING



At Why Summits, you won't get lost in the crowd. Designed for **100+ senior leaders by invitation only**, we foster meaningful, strategic discussions in an **intimate, interactive environment**.

Interactive Networking

Numerous opportunities to meet with participants multiple times over two days

Tailored Discussions

Dive deep into hurdles, share visions, and secure a future-ready PV process

Healthy Participant Ratios

75% industry stakeholders, 25% solution providers — ensuring collaboration and avoiding over-pitching



WHO ATTENDS?

VPs, Global Heads, and Senior Directors from fields such as:

- Drug safety & Pharmacovigilance executives
- Heads of global safety programs
- QPPVs
- Benefit-Risk assessment management
- Medical affairs management
- Patient safety management
- Compliance specialists
- Post-market researches
- PV auditors
- Regulatory affairs directors
- EMA professionals
- Compliance specialists
- Pharma IT management
- Safety consultants



WHY ATTEND?

The event offers an unparalleled opportunity to



BENCHMARK INNOVATIONS:

Learn how top organizations navigate challenges in Drug Safety and Pharmacovigilance



PILOT NEW SOLUTIONS:

Explore small-scale implementation projects with potential for organization-wide adoption



LEVERAGE EXPERTISE:

Engage with professionals boasting 10+, 15+, or 20+ years of PV experience

TESTIMONIALS



Andrew Mitchell

Chief Executive Officer
YEZA.ai



"WhySummit's Pharmacovigilance Conference in Boston exceeded expectations for all. As chair, I was impressed by the intimate scale and quality of interactions given how tricky it can be to strike the right balance of being large enough to bring together diverse perspectives and new connections, yet small enough to foster meaningful dialogue and substantive interactions. Both sponsors and attendees valued lively discussions that went beyond typical sessions (and without being overly 'salesy'). Lubos and his team deserve credit for curating a program that was both informative and interactive, creating an environment where PV professionals could truly connect, share and learn from each other. Looking forward to next year."



Apoorva Anil Joshi

Senior Pharmacovigilance Product Scientist
Genentech



"The American Drug Safety Summit 2025 was a great event to learn from industry experts about the evolution of patient safety. It was very interesting to see how AI is being leveraged in data-intensive projects to improve patient outcomes. The introduction to the REMS Industry Consortium was a highlight, and their work is truly inspiring."



Marissa StLouis

Safety Partnering Lead
Genentech



"Excited to have participated in the American Drug Safety Summit in Boston, MA! 🎉. It was an honor to highlight the successful partnerships and collaborations between our Safety and Social teams over the past couple of years as well as connect and learn from with industry Subject Matter Experts. A key takeaway for me: AI is coming/ AI is now- How can we utilize this tool, not only to bring efficiencies into our work, but also focus on value-add and increasing quality of work? Thank you to Alison Purdon for your sponsorship and mentorship over the past several years and inviting me to join in on this opportunity! Thank you to Lubos K. and the #WhySummits team for all of your partnership and efforts creating a memorable event!"



Mina Ebeid

Director, Global Drug Safety
Genmab



"I thoroughly enjoyed participating in the Why Summits pharmacovigilance conference. The topics were not only timely and relevant but also deeply engaging, sparking meaningful discussions. I especially appreciated the collaborative atmosphere, which created a great opportunity to connect with colleagues across the field and exchange valuable insights."



Robert Huber

Co-Founder and Chief Product Officer
Veridat



"Fabulous meeting today, Lubos. This is a fabulous opportunity for us to shape the future, not just that we can be the conduit to current advances, but we can go beyond that with our military grade solutions."



Vasudev Sureddy

Executive Director & COO
ADVITY RESEARCH



"This event provided great opportunity to network with industry peers & thought leaders and explore new ways of working. Especially in the new AI era; "on how Pharmacovigilance industry is progressing and how we need to adapt to the change". Insights from presentations and panel discussions are adorable. I left with great ideas and new connections in my network to collaborate with and grow further."



Israel Bocanegra

Associate Director, Business Development
Pharmacovigilance Technology Solutions



"I want to express my gratitude to Lubos and the Why Summits team for a well-organized and informative Pharmacovigilance event. The comprehensive agenda, featuring a variety of expert presenters and engaging panel discussions, provided valuable insights and fostered productive networking. I'm eager to participate in future Why Summits events."



Katarina Ilic

Expert Consultant
Drug Safety, Clinical Pharmacology, Clinical Development, Pharmacoepidemiology



"I heard great things about the event from those who attended, and those who didn't manage to attend this year regret."



Alison Purdon

Senior Director, MedOps, Quality & Compliance, Engagement Oversight
Genentech



"The event was incredibly well-organized, and we enjoyed both the thoughtful conversations and the chance to connect with others in the industry. Your efforts in bringing together leaders in drug safety to drive meaningful dialogue do not go unnoticed, and we are grateful to have been a part of it. Thank you again for your kind invitation and for making the experience such a great one. I look forward to staying in touch and continuing the conversation!"



Kal Elhoregy, RPh., PA.

Senior Director, Global Risk Management
Amneal



"The conference fosters invaluable connections and drives meaningful collaboration, offering an engaging platform for dynamic interactions within Global Pharmacovigilance & Risk Management, exchange of ideas, and shared growth among participants to ensure patient safety and regulatory compliance."



Karthik Babu

Consumer Healthcare Global PV Operations Head
Sanofi



"I thoroughly enjoyed the interactive and spontaneous discussions on key pharmacovigilance topics, ranging from Gen AI to PV regulatory frameworks. The conference brought together a focused group of PV professionals, providing ample opportunities to connect and network with like-minded individuals. Overall, it was a successful conference and met its objectives."

INDUSTRY LEADERS JOINING US



GSK



Lilly



Roche

sanofi



abbvie



Johnson & Johnson

AMGEN



teva



CSL™



SANDOZ

BIONTECH

moderna®

OUR VALUED PARTNERS, PAST AND PRESENT



OUR VALUED SPEAKERS, PAST AND PRESENT



Galyna Cordero

QPPV, Head of pharmacovigilance
JSC Farmak



Sanket Mahajan

Safety Scientist,
Pharmacovigilance
Shionogi Europe
Shionogi Europe



Stefanie Amend-Mall

Director Patient Safety HUB
Europe
Sandoz



Darko Krnic

Head of Pharmacovigilance
Pharma&



Ivanna Mikhailovna Rosendal

Senior Director, Global Head of Digitalization
Ascendis Pharma



Mark Cawley

Associate Director, Research Procurement (Reg Affairs, PV & Med Affairs)
Jazz Pharmaceuticals



Offiong Ani

Associate Director, Third Party Strategy & Oversight, Worldwide Patient Safety
Bristol Myers Squibb



Annette Humes

Global Head of Safety Resource & Alliance Management and Chief of Staff (Safety)
F Hoffmann La Roche



Gurpreet Singh

Vice President, Managing Director Integrated Safety
IQVIA



Santiago Schiaffino

Senior Director, Patient Safety Biopharma - Global Patient Safety Biopharma Organization | R&D CMO
AstraZeneca



Gaetano Aiello

Sr Manager, EU/International PV & QPPV Office and PSMF Admin
Jazz Pharmaceuticals



Nicole Baker

CEO
BioLogit



Emerson Welch

VP Global Marketing
Quark



Carlos de Pablos Martínez

QPPV Office Specialist
Argenx



Dr. Joan D'souza

Pharmacovigilance and Quality Consultant (DACH region)



Dr Siva Kumar

Director Global Safety
Amgen



Andrew Mitchell

Founder
YEZA.AI



Liz Grekas

Director, Global Safety Lead
Novo Nordisk

OUR VALUED SPEAKERS, PAST AND PRESENT



Priyanka Chhikara

Senior Director, Head of Pharmacovigilance Scientists
CSL



Sameen Desai

Executive Director, Head of WorldWide Patient Safety IT
Bristol Myers Squibb



Ashraf Youssef

Global Senior Medical Director, Post Marketed Products, Global Safety Lead
Takeda



Kamal Shah

VP PV&DS
Veloxis Pharmaceuticals



Kal Elhoregy

Senior Director, Global Risk Management & Pharmacovigilance Compliance – Global Patient Safety
Amneal Pharmaceuticals



Karen Schriemer De Jong

Executive Director GPV Global Case Management
Boehringer Ingelheim



TBA

Global Risk Management Leader – Oncology
Bristol Myers Squibb



Manjiri Nirgudkar

Director, Global Risk Management
Bristol Myers Squibb



Kamlesh Prabhu

Director PV
BioNTech



Harsh Bhatt

Production & PV Supervisor
Apnar Pharma



Kyle Irwin

Director REMS & Risk Management
J&J Innovative Medicine



Deepa Venkataraman

VP Drug Safety & PV
Summit Therapeutics



Sean Green (TBC)

Director, Safety Database Strategy and Analytics at Apellis Pharmaceuticals
Apellis



Dr. Karthik Muthusamy

Senior Director, Head Expedited Safety Reporting
Bristol Myers Squibb



Mariette Boerstael Streefland

SVP, Worldwide Patient Safety Officer
Bristol Myers Squibb



Aysha Amman

Senior Director, Head of Global Patient Safety and Pharmacovigilance
Amneal Pharmaceuticals



Emerson Welch

VP Global Marketing
Quark



Asif Mahmood

Vice President, Head of Medical Safety & Pharmacovigilance
AskBio

Contact us to explore partnership opportunities:



SPEAKING:

Jan Cizek

jan.cizek@whysummits.com



ATTENDING AND SPONSORING:

Lubos Kusy

lubos@whysummits.com



ATTENDING AND SPONSORING:

Rakesh Multani

rakesh@whysummits.com

Follow our Social Media:

